News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,929 Results
Type
Article (40920)
Company Profile (267)
Press Release (680732)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204672)
Career Advice (2024)
Deals (35532)
Drug Delivery (110)
Drug Development (81384)
Employer Resources (173)
FDA (16414)
Job Trends (14945)
News (346395)
Policy (32727)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2568)
Accelerated approval (33)
Adcomms (24)
Allergies (142)
Alliances (49575)
ALS (169)
Alzheimer's disease (1669)
Antibody-drug conjugate (ADC) (313)
Approvals (16686)
Artificial intelligence (515)
Autoimmune disease (159)
Automation (41)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (191)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (57)
Breast cancer (640)
Cancer (4822)
Cardiovascular disease (399)
Career advice (1709)
Career pathing (36)
CAR-T (282)
CDC (44)
Celiac Disease (2)
Cell therapy (745)
Cervical cancer (36)
Clinical research (69588)
Collaboration (1706)
Company closure (4)
Compensation (1165)
Complete response letters (56)
COVID-19 (2712)
CRISPR (92)
C-suite (851)
Cystic fibrosis (143)
Data (6252)
Decentralized trials (2)
Denatured (25)
Depression (134)
Diabetes (502)
Diagnostics (6696)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (253)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (232)
Earnings (90213)
Editorial (57)
Employer branding (21)
Employer resources (152)
Events (117321)
Executive appointments (977)
FDA (19544)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1471)
Gene editing (198)
Generative AI (43)
Gene therapy (597)
GLP-1 (966)
Government (4660)
Grass and pollen (6)
Guidances (384)
Healthcare (18876)
HIV (60)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (252)
Immuno-oncology (57)
Indications (114)
Infectious disease (2984)
Inflammatory bowel disease (191)
Inflation Reduction Act (14)
Influenza (117)
Intellectual property (252)
Interviews (315)
IPO (16643)
IRA (50)
Job creations (3642)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (86)
Layoffs (547)
Leadership (32)
Legal (7950)
Liver cancer (91)
Longevity (14)
Lung cancer (650)
Lymphoma (379)
Machine learning (42)
Management (59)
Manufacturing (799)
MASH (164)
Medical device (13773)
Medtech (13827)
Mergers & acquisitions (19964)
Metabolic disorders (1270)
Multiple sclerosis (163)
NASH (16)
Neurodegenerative disease (316)
Neuropsychiatric disorders (88)
Neuroscience (2903)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4515)
Now hiring (67)
Obesity (596)
Opinion (261)
Ovarian cancer (166)
Pain (198)
Pancreatic cancer (227)
Parkinson's disease (280)
Partnered (33)
Patents (500)
Patient recruitment (492)
Peanut (56)
People (58882)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21691)
Phase 2 (30624)
Phase 3 (22817)
Pipeline (5354)
Policy (283)
Postmarket research (2564)
Preclinical (9199)
Press Release (64)
Prostate cancer (238)
Psychedelics (48)
Radiopharmaceuticals (282)
Rare diseases (839)
Real estate (5954)
Recruiting (70)
Regulatory (24509)
Reports (53)
Research institute (2389)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (78)
Schizophrenia (148)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (97)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3615)
State (2)
Stomach cancer (17)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1008)
Venture capital (89)
Weight loss (381)
Women's health (92)
Worklife (18)
Date
Today (183)
Last 7 days (551)
Last 30 days (2216)
Last 365 days (29901)
2026 (3658)
2025 (30172)
2024 (35216)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39228)
Australia (6410)
California (11330)
Canada (3297)
China (1101)
Colorado (479)
Connecticut (479)
Delaware (339)
Europe (84561)
Florida (1696)
Georgia (357)
Hawaii (3)
Idaho (61)
Illinois (864)
India (67)
Indiana (523)
Iowa (22)
Japan (432)
Kansas (127)
Kentucky (39)
Louisiana (26)
Maine (72)
Maryland (1383)
Massachusetts (8098)
Michigan (326)
Minnesota (629)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (3009)
New Mexico (28)
New York (2986)
North Carolina (1458)
North Dakota (8)
Northern California (5540)
Ohio (334)
Oklahoma (21)
Oregon (41)
Pennsylvania (2285)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (66)
South Dakota (1)
Southern California (4411)
Tennessee (175)
Texas (1746)
United States (40140)
Utah (337)
Vermont (1)
Virginia (263)
Washington D.C. (81)
Washington State (923)
West Virginia (4)
Wisconsin (109)
Wyoming (2)
721,929 Results for "vaxcyte inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 6, 2026
·
2 min read
Press Releases
Vaxcyte Announces Pricing of $550 Million Public Offering
January 30, 2026
·
4 min read
Press Releases
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 3, 2026
·
3 min read
Press Releases
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
February 11, 2026
·
2 min read
Press Releases
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 12, 2026
·
11 min read
Press Releases
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 23, 2026
·
17 min read
Press Releases
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
November 4, 2025
·
16 min read
Press Releases
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
December 8, 2025
·
15 min read
Press Releases
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
October 1, 2025
·
4 min read
Press Releases
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
September 3, 2025
·
10 min read
1 of 72,193
Next
